JPS6293229A - 免疫調節剤 - Google Patents
免疫調節剤Info
- Publication number
- JPS6293229A JPS6293229A JP23414485A JP23414485A JPS6293229A JP S6293229 A JPS6293229 A JP S6293229A JP 23414485 A JP23414485 A JP 23414485A JP 23414485 A JP23414485 A JP 23414485A JP S6293229 A JPS6293229 A JP S6293229A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- oxazepam
- immune
- acid adduct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940124644 immune regulator Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 11
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960004535 oxazepam Drugs 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 9
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims abstract description 8
- 229960004391 lorazepam Drugs 0.000 claims abstract description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 4
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 3
- 150000002367 halogens Chemical class 0.000 claims abstract description 3
- 239000002955 immunomodulating agent Substances 0.000 claims description 8
- 229940121354 immunomodulator Drugs 0.000 claims description 7
- 230000002584 immunomodulator Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 abstract description 8
- 229960003529 diazepam Drugs 0.000 abstract description 8
- 230000028993 immune response Effects 0.000 abstract description 5
- 201000011510 cancer Diseases 0.000 abstract description 2
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229940049706 benzodiazepine Drugs 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- XBWAZCLHZCFCGK-UHFFFAOYSA-N 7-chloro-1-methyl-5-phenyl-3,4-dihydro-2h-1,4-benzodiazepin-1-ium;chloride Chemical compound [Cl-].C12=CC(Cl)=CC=C2[NH+](C)CCN=C1C1=CC=CC=C1 XBWAZCLHZCFCGK-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 229920006926 PFC Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- -1 lorazebam Chemical compound 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 229960002225 medazepam Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- VCCZBYPHZRWKFY-XIKOKIGWSA-N oxazolam Chemical compound C1([C@]23C4=CC(Cl)=CC=C4NC(=O)CN2C[C@H](O3)C)=CC=CC=C1 VCCZBYPHZRWKFY-XIKOKIGWSA-N 0.000 description 1
- 229950006124 oxazolam Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23414485A JPS6293229A (ja) | 1985-10-18 | 1985-10-18 | 免疫調節剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23414485A JPS6293229A (ja) | 1985-10-18 | 1985-10-18 | 免疫調節剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6293229A true JPS6293229A (ja) | 1987-04-28 |
| JPH0482131B2 JPH0482131B2 (enrdf_load_stackoverflow) | 1992-12-25 |
Family
ID=16966330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP23414485A Granted JPS6293229A (ja) | 1985-10-18 | 1985-10-18 | 免疫調節剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6293229A (enrdf_load_stackoverflow) |
-
1985
- 1985-10-18 JP JP23414485A patent/JPS6293229A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0482131B2 (enrdf_load_stackoverflow) | 1992-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3789239T2 (de) | Pharmazeutische Zusammensetzung enthaltend Interferon für bukkale Verabreichung. | |
| AU686656B2 (en) | Compositions containing piperine | |
| FI102755B (fi) | Menetelmä uuden, terapeuttisesti käyttökelpoisen yhdisteen tai sen suo lan valmistamiseksi | |
| WO2018090983A9 (zh) | 改善肠道菌群的皂苷类化合物、制备方法及其应用 | |
| JP2572558B2 (ja) | ポドフイロトキシンよりなるマラリヤの治療剤 | |
| RU2033157C1 (ru) | Средство, обладающее интерферониндуцирующей и иммуномодулирующей (иммуностимулирующей) активностью | |
| JPS60184011A (ja) | 免疫調節剤 | |
| US4039656A (en) | Production of attenuated viruses | |
| KR0169982B1 (ko) | 피부염 치료용 약제 | |
| JPS6293229A (ja) | 免疫調節剤 | |
| US4049794A (en) | Treatment of infections in animals | |
| WO1994000126A1 (en) | The use of bile acids as antiviral agents | |
| JPS63264527A (ja) | 抗エイズウイルス剤 | |
| AU594449B2 (en) | Tripeptide with immunostimulating activity | |
| JP4580479B2 (ja) | 抗ｈｉｖ感染症剤 | |
| Mattia et al. | Effectiveness of thymostimulin and study of lymphocyte-dependent antibacterial activity in children with recurrent respiratory infections | |
| EP0476391B1 (en) | Anti-AIDS virus composition containing cepharanthine as active compound | |
| US4529543A (en) | Hepatosin | |
| US4017359A (en) | Production of non-antigenic attenuated viruses | |
| JPH029600B2 (enrdf_load_stackoverflow) | ||
| Park et al. | Clinical trial of cefotaxime in patients with typhoid fever | |
| JPH0214331B2 (enrdf_load_stackoverflow) | ||
| CN115554301A (zh) | Hdac抑制剂和伊布替尼在制备预防或者治疗套细胞淋巴瘤的药物中的用途 | |
| JPS58167514A (ja) | 免疫調整剤 | |
| JPS61145118A (ja) | 免疫調節剤 |